NLS Pharmaceutics Partners for Gene-Edited Cell Therapies
Ticker: NCEL · Form: 6-K · Filed: Oct 27, 2025 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Oct 27, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: collaboration, biotech, cell therapy, gene editing
TL;DR
NLS Pharma inks deal with Kadimastem to boost gene-edited cell therapy tech.
AI Summary
On October 27, 2025, NLS Pharmaceutics Ltd. announced a strategic collaboration between its subsidiary TargetGene and Kadimastem. This partnership aims to advance next-generation gene-edited cell therapies.
Why It Matters
This collaboration could accelerate the development of innovative cell therapies, potentially leading to new treatments for various diseases.
Risk Assessment
Risk Level: medium — Strategic collaborations in the biotech sector carry inherent risks related to development timelines, regulatory approvals, and market adoption.
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — Registrant and collaborator
- Kadimastem (company) — Collaborator
- TargetGene (company) — Subsidiary of NLS Pharmaceutics
- October 27, 2025 (date) — Date of press release
FAQ
What is the primary goal of the strategic collaboration between NLS Pharmaceutics' subsidiary TargetGene and Kadimastem?
The primary goal is to advance next-generation gene-edited cell therapies.
Which subsidiary of NLS Pharmaceutics is involved in this collaboration?
TargetGene is the subsidiary of NLS Pharmaceutics involved in the collaboration.
What type of therapies does this collaboration aim to advance?
The collaboration aims to advance next-generation gene-edited cell therapies.
On what date was the press release announcing this collaboration issued?
The press release was issued on October 27, 2025.
What is the Commission File Number for NLS Pharmaceutics Ltd.?
The Commission File Number for NLS Pharmaceutics Ltd. is 001-39957.
Filing Stats: 214 words · 1 min read · ~1 pages · Grade level 12 · Accepted 2025-10-27 07:17:00
Filing Documents
- ea0262581-6k_nlspharma.htm (6-K) — 10KB
- ea026258101ex99-1_nlspharma.htm (EX-99.1) — 16KB
- ex99-1_001.jpg (GRAPHIC) — 24KB
- 0001213900-25-102346.txt ( ) — 60KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: October 27, 2025 By: /s/ Alexander C. Zwyer Name: Alexander C. Zwyer Title: Chief Executive Officer 2